Naltrexone/bupropion for bingeâeating disorder: A randomized, doubleâblind, placeboâcontrolled trial
Grilo C, Lydecker J, Jastreboff A, Pittman B, McKee S. Naltrexone/bupropion for bingeâeating disorder: A randomized, doubleâblind, placeboâcontrolled trial. Obesity 2023, 31: 2762-2773. PMID: 37751990, PMCID: PMC10600891, DOI: 10.1002/oby.23898.Peer-Reviewed Original ResearchConceptsNaltrexone/bupropionBinge-eating disorderObesity statusLogistic regressionWeight lossPlacebo-controlled trialWeight loss outcomesPrevalent psychiatric disordersEvidence-based treatmentsPost-treatment assessmentBinge-eating frequencyGreater percentage weight lossMedication outcomesRemission ratePharmacological optionsPlaceboBupropionPsychiatric disordersPercentage weight lossMixed modelsDisordersObesityPatientsSignificant reductionWeight reduction